This article was originally published in The Tan Sheet
Dietary supplements containing the patented compound Lepitrim are expected to reach the market through direct sellers by the end of the first quarter of 2006, Imagenetix announces. Expansion to mass market distribution is expected in the second quarter. The San Diego, Calif.-based firm signed a licensing agreement with the University of Minnesota and will market the ingredient as a raw material, according to a Nov. 16 announcement. Lepitrim lowers levels of leptin, a hormone that causes fat storage. When leptin levels are low, fat is released to be burned as energy by the body, Imagenetix says. A one-month supply is expected to cost $55 - $65. The firm is submitting structure/function claims that include "Assists in lowering body fat" and "Promotes the reduction of stored fat by increasing fatty acid utilization in the fat cell"...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.